US 7,351,729 B2 · JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers

Abstract

The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more inhibitors of JNK in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more inhibitors of JNK in combination with one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of an effective amount of one or more inhibitors of JNK in combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies/immunotherapies and/or radiation therapies for treatment or prevention of cancer. Also included are methods of treatment of cancer by the administration of one or more inhibitors of JNK in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, bone marrow transplants, stem cell replacement therapies, biological therapies/immunotherapies and/or radiation therapies.

Claims8

Dependent claims

A method for treating lung cancer or leukemia in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of one or more JNK inhibitors and a therapeutically effective amount of a chemotherapeutic agent, wherein the JNK inhibitor is:

wherein:
(a) -A-R1 is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, —NR8C(═O)R9, —C(═O)NR8R9, and —O(CH2)bNR8R9, wherein b is 2 or 3 and R8 and R9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocycloalkyl, or R8 and R9 taken together with the atom or atoms to which they are bonded form a heterocycle;
and
(b) R2 is 3-triazolyl or 5-tetrazolyl;
or a pharmaceutically acceptable salt thereof.

2 more elements

Dependencies are inferred from the claim text.

JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers

Life of this patent

JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers

Life of this patent

Abstract

Claims8